Back to results
US 12,590,301 B2Granted
Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
AssigneeThrombolytic Science, Inc.
InventorVictor Gurewich
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).
Claims16
A method of treating a subject with symptoms of a stroke or an acute myocardial infarction (AMI), the method comprising:
- (a) identifying a subject who potentially had a stroke or an AMI by observing one or more symptoms of a stroke or an AMI without determining the cause of the stroke or AMI;
- and
- (b) administering to the subject a combination therapy comprising
- (i) a bolus of a first composition comprising less than 5 mg of tissue plasminogen activator (tPA), followed by
- (ii) an intravenous infusion of a second composition comprising a mutant form of wild-type human pro-urokinase having a single point mutation in one of amino acid positions 297-313 thereof (mproUK), wherein the wild-type human pro-urokinase has an amino acid sequence of SEQ ID NO:
- 1, infused over 60 to 90 minutes at a rate of 60 to 80 mg/hour;
- wherein the combination therapy achieves a clot lysis rate having a Thrombolysis In Myocardial Infarction (TIMI) score of 2 or higher with a level of fibrinogen degradation in the subject's blood of less than about 30 percent.
4 more elements
Dependencies are inferred from the claim text.